Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Globe Newswire•16/11/2026•06:00 ET
0
Key Highlights
- ➤Net loss $103.1 million, versus $33.7 million year-over-year
- ➤Cash totaled $171.1 million as of September 30, 2026
- ➤APPROACH Phase 3 enrolled 223 adults; topline data remains on track for Q4 2026
- ➤HLP004 Phase 2 GAD monotherapy study expected to initiate in Q1 2027
- ➤HLP005 drug development candidate anticipated in the second half of 2027
Expert Statements
Michael Halstead, Chief Executive Officer of Helus Pharma
“Since joining Helus Pharma as Chief Executive Officer, I have had the opportunity to work closely with our teams and gain a deep appreciation for the potential our development programs have to positively impact the treatment of mental health related conditions and the dedication of our employees.”
Michael Halstead, Chief Executive Officer of Helus Pharma
“We continue to expect topline results from the APPROACH study in the fourth quarter of 2026, and we remain focused on disciplined execution across our portfolio. With enrollment ongoing in the EMBRACE and EXTEND studies in our Phase 3 adjunctive MDD program and the anticipated initiation of our Phase 2 HLP004 monotherapy study in generalized anxiety disorder in the first quarter of 2027, we believe we are well positioned to continue to advance our pipeline to deliver important treatments to patients.”
Appointed Michael Halstead as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization
Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder (“MDD”); topline data remains on track for Q4 2026(1)(,)(2)
Get started
Create a free account to read the full story.
